Page 87 - Read Online

Lorenzin et al. J Transl Genet Genom 2019;3:5. I https://doi.org/10.20517/jtgg.2019.01 Page 9 of 12

Nature 2012;487:239-43.
24. Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced
and lethal prostate cancers. Proc Natl Acad Sci U S A 2011;108:17087-92.
25. Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer
2015;15:701-11.
26. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, et al. In vivo amplification of the androgen receptor gene and progression of
human prostate cancer. Nat Genet 1995;9:401-6.
27. Menon R, Deng M, Ruenauver K, Queisser A, Peifer M, et al. Somatic copy number alterations by whole-exome sequencing implicates
YWHAZ and PTK2 in castration-resistant prostate cancer. J Pathol 2013;231:505-16.
28. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, et al. Integrative clinical genomics of advanced prostate cancer. Cell
2015;161:1215-28.
29. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, et al. Amplification and overexpression of androgen receptor gene in
hormone-refractory prostate cancer. Cancer Res 2001;61:3550-5.
30. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, et al. Androgen receptor gene amplification at primary progression
predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000;164:1992-5.
31. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, et al. Increased expression of androgen receptor sensitizes prostate cancer cells to
low levels of androgens. Cancer Res 2009;69:8141-9.
32. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-
9.
33. Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, et al. Structural alterations driving castration-resistant prostate cancer revealed
by linked-read genome sequencing. Cell 2018;174:433-47.e19.
34. Takeda DY, Spisak S, Seo JH, Bell C, O’Connor E, et al. A somatically acquired enhancer of the androgen receptor is a noncoding driver in
advanced prostate cancer. Cell 2018;174:422-32.e13.
35. Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, et al. Targeted next-generation sequencing of advanced prostate cancer
identifies potential therapeutic targets and disease heterogeneity. European urology 2013;63:920-6.
36. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, et al. Mutation of the androgen-receptor gene in metastatic androgen-
independent prostate cancer. N Engl J Med 1995;332:1393-8.
37. Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers
of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res 2015;21:2315-24.
38. Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, et al. Androgen receptor gene status in plasma DNA
associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative
biomarker study. Ann Oncol 2017;28:1508-16.
39. Romanel A, Tandefelt DG, Conteduca V, Jayaram A, Casiraghi N, et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med
2015;7:312re10.
40. Wyatt AW, Azad AA, Volik SV, Annala M, Beja K, et al. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-
resistant prostate cancer. JAMA Oncol 2016;2:1598-606.
41. Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med
2014;6:254ra125.
42. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, et al. A clinically relevant androgen receptor mutation confers resistance to second-
generation antiandrogens enzalutamide and ARN-509. Cancer Discov 2013;3:1020-9.
43. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, et al. A mutation in the ligand binding domain of the androgen
receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun
1990;173:534-40.
44. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, et al. Overcoming mutation-based resistance to antiandrogens with rational
drug design. Elife 2013;2:e00499.
45. Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, et al. Abiraterone treatment in castration-resistant prostate cancer selects for
progesterone responsive mutant androgen receptors. Clin Cancer Res 2015;21:1273-80.
46. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, et al. Glucocorticoids can promote androgen-independent growth of prostate
cancer cells through a mutated androgen receptor. Nat Med 2000;6:703-6.
47. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the
androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997;11:450-9.
48. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active
androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68:5469-77.
49. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons
signify hormone-refractory prostate cancer. Cancer Res 2009;69:16-22.
50. Lu J, Lonergan PE, Nacusi LP, Wang L, Schmidt LJ, et al. The cistrome and gene signature of androgen receptor splice variants in castration
resistant prostate cancer cells. J Urol 2015;193:690-8.
51. Chan SC, Selth LA, Li Y, Nyquist MD, Miao L, et al. Targeting chromatin binding regulation of constitutively active AR variants to
overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res 2015;43:5880-97.
52. Guo Z, Yang X, Sun F, Jiang R, Linn DE, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression